Severe cutaneous adverse drug reactions: A review on epidemiology, etiology, clinical manifestation and pathogenesis

Chinese Medical Journal

Volumn 121, Issue 8, 2008, Pages 756-761

  Martin, Tom ^a,b   Li, Hui ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b NONE   (China)

Author keywords

Drug hypersensitivity syndrome; Exfoliative dermatitis; Severe cutaneous adverse drug eruptions; Steven Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; ANTIRHEUMATIC AGENT; AYURVEDIC DRUG; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHINESE DRUG; CIMETIDINE; CORTICOSTEROID; GOLD; LITHIUM; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE; PENICILLIN G; PHENOBARBITAL; PHENYTOIN; QUINIDINE; RANITIDINE; SALAZOSULFAPYRIDINE; SULFONAMIDE; THYROID HORMONE DERIVATIVE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID;

AGE; ALLELE; ASIA; CHINESE; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; DRESS SYNDROME; EPIDEMIOLOGICAL DATA; EXFOLIATIVE DERMATITIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; INCIDENCE; MEDICAL LITERATURE; MEDLINE; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SYMPTOM; TOXIC EPIDERMAL NECROLYSIS; TRADITIONAL MEDICINE; VIRUS INFECTION;

EID: 51149088076     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200804020-00019     Document Type: Review

References (49)

1. Champion RH, Burton JL, Burns DA, Breathnach SM. Textbook of dermatology. 6th ed. Oxford: Blackwell Science Publishing 1998; 2085-2087.
2. Irwin MF, Arthur ZE, Klauss WK, Frank A, Lowell AG, Stephen K. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw Hill 1999; 138.
3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-1285.
4. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839-846.
5. Hunziker T, Künzi UP, Braunschweig S, Zehnder D, Hoigné R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-393.
6. Fiszenson AF, Auzerie V, Mahe E, Farinotti R, Durand SC, Crickx B, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018-1022.
7. Yigit S, Korkmaz A, Sekerel B. Drug-induced hypersensitivity syndrome in a premature infant. Ped Dermatol 2005; 22: 71-74.
8. Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: a synopsis. Int J Dermatol 2004; 43: 39-47.
9. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 2006; 31: 642-647.
10. Noel MV, Sushma M, Guido S. Cutaneous adverse drug reactions in hospitalized patients in a tertiary care center. India J Pharmacol 2004; 36: 292-295.
11. Puavilai S, Choonhakarn C. Drug eruptions in Bangkok: a 1 year study at Ramathibodi hospital. Int J Dermatol 1998; 37: 747-751.
12. Wan MJ, Lia W, Su. XY, Lu C, Huang HQ, Zhu GX, et al. Clinical analysis of 17 patients with drug hypersensitivity syndrome. J Clin Dermatol 2004; 33: 463-464.
13. Conilleau V, Dompmartin A, Verneuil L, Michel M, Leroy D. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis 1999; 41: 141-144.
14. Xiong L, Xie Y. Clinical analysis of 64 patients with Severe Drug Eruptions. Chin J Curr Clin Med 2003; 1: 1027-1028.
15. Zhong JN. Clinical analysis of 33 investigation with severe drug eruption. Pract Med Tech 2006; 5: 913-915.
16. Lv XH. Clinical analysis of 28 investigation with severe drug eruption. Zhejiang J Clin Med 2005; 7: 950.
17. Li CX, Zhang XB, Wu ZH. Clinical analysis of 35 patients with severe drug eruption. Youjiang Med J 2004; 32: 149-150.
18. Martin R, Biswas PN, Freemantle SN, Pearce GL. Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505-511.
19. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician 2003; 68: 1781-1790.
20. Collen F. Women and adverse drug reactions reporting in Canadian context. Women and health protection 2002: 12-14.
21. Ma CH. Statistical analysis of 39 patients with severe drug eruptions. Chin Rust Med J 2001; 8: 36-37.
22. Qi BQ, Duan XS, Zhang CM, Yu ZW, Li BQ. Clinical analysis of 31 patients with severe drug eruptions. Chengde Med College J 2002; 19: 18-19.
23. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309-316.
24. Peyrière H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, Hillaire B. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155: 422-428.
25. Leenutaphong V, Sivayathom A, Suthipinittharm P, Sunthonpalin P. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993; 32: 428-431.
26. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5.
27. Kamaliah MD, Zainal D, Mokhtar N, Nazmi N. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol 1998; 37: 520-523.
28. Jesse BH, Gregory AS, Lawrence DHW. Principles of Critical Care, 3rd ed. NewYork: McGraw-Hill Companies 2005 (accesed October 7, 1007 at http://www.accessmedicine.com/content.aspx?aID=2281931)
29. Vanfleteren I, Van GD, De BC. Stevens-Johnson syndrome: a diagnostic challenge in the absence of skin lesions. Pediatr Dermatol 2003; 20: 52-56.
30. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156: 1083-1084.
31. Devi K, George S, Criton S, Suja V, Sridevi PK, Carbamazepine - the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol 2005; 71: 325-328.
32. Takahashi H, Tanaka M, Tanikawa A, Toyohara A, Ogo Y, Morimoto A, et al. A case of drug-induced hypersensitivity-syndrome showing transient immunosuppression before viral reactivation during treatment for pemphigus foliaceus. Clin Exp Dermatol 2006; 31: 33-35.
33. KA Oshikoya, OF Njokamna, HA Chukwura. Adverse drug reaction in Nigerian children. Paed Perinat Drug Ther 2007; 8: 81-88.
34. Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Risk estimates for drugs suspected of being associated with Steven-Johnson syndrome and Toxic epidermal necrolysis: a case control study. Intern Med J 2005; 35: 188-190.
35. Lin CC, Wu JC, Huang DF, Huang YS, Huang YH, Huo TI, et al. Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases. J Gastroenterol Hepatol 2001; 16: 481-483.
36. Piskin G, Mekkes JR. Stevens-Johnson syndrome from metronidazole. Contact Dermatitis 2006; 55: 192-193.
37. Teo L, Tan E. Sulphasalazine-induced DRESS. Singapore Med J 2006; 47: 237-239.
38. Sehgal VN, Srivastava G Erythroderma/generalized exfoliative dermatitis in pediatric practice: an overview. Int J Dermatol 2006; 45: 831-839.
39. Demoly P, Viola M, Gomes ER, Romano A. Drug hypersensitivity. Basel; Karger AG 2007: 2-17.
40. Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr 2006; 6: 33-37.
41. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-1018.
42. Chia FL, Leong KP. Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol 2007; 7: 304-309.
43. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7: 324-330.
44. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schöpf E. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4: 313-316.
45. Criado, PR, Criado RF, Vasconcellos C, Pegas JR, Cera PC. Severe cutaneous adverse reactions to drug-relevant aspect to diagnosis and treatment. An Bras Dermatol 2004; 79: 471-488.
46. Pirmohamed M, Park BK. Adverse drug reactions: back to the future. Br J Clin Pharmacol 2003; 55: 486-492.
47. Bachot N, Roujeau JC. Physiopathology and treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 2001; 1: 293-298.
48. Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155: 722-728.
49. Higuchi M, Agatsuma T, Iizima M, Yamazaki Y, Saita T, Ichikawa T, et al. A case of drug-induced hypersensitivity syndrome with multiple organ involvement treated with Plasma exchange. Ther Apher Dial 2005; 9: 412-416.